AI assistant
Sending…
PMV Pharmaceuticals, Inc. — Director's Dealing 2022
Feb 28, 2022
34350_dirs_2022-02-28_0ebf4c54-86c0-4017-a425-4958abe969a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2022-02-10
Reporting Person: Jalota Deepika (SVP, Regulatory Affairs and QA)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-10 | Employee Stock Option (right to buy) | $16.29 | A | 68100 | Acquired | 2032-02-10 | Common Stock (68100) | Direct |
Footnotes
F1: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.
More from PMV Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 9
Interim / Quarterly Report
2025
Nov 12
Regulatory Filings
2025
Nov 12
Major Shareholding Notification
2025
Nov 12
Director's Dealing
2025
Oct 29